Opinion
Video
Author(s):
CT1812 Meets Primary End Point in Phase 2 SHIMMER Study for Dementia with Lewy Bodies
Episode 130: The Promise Behind Cell Therapy Approaches in Epilepsy
NeurologyLive® Friday 5 — December 20, 2024
Episode 129: Implications of the 2024 AASM Guidelines for Restless Legs Syndrome
Parkinson Agent Prasinezumab Misses Primary End Point But Shows Positive Effects in Other Outcomes
FDA Grants MDA Kickstart Program Rare Pediatric Disease Designation and Orphan Drug Designation in Congenital Myasthenic Syndrome